Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer
Karacetin, D.; Yalcin, B.; Okten, B.; Ozturk, S.; Maral, O.; Incekara, O.
Journal of BUON Official Journal of the Balkan Union of Oncology 14(4): 605-608
2009
ISSN/ISBN: 1107-0625 PMID: 20148449 Document Number: 11293
For almost 40 years, 5-fluorouracil (5-FU) had been the only drug with demonstrated activity against (CRC), commonly used in combination with leucovorin (LV). Oxaliplatin and capecitabine are two relatively novel drugs used in the treatment of CRC. These drugs have been found to act synergistically, both in vivo and in vitro and their combination (XELOX) is highly active in metastatic colorectal cancer (mCRC). The aim of this study was to determine the safety and efficacy of XELOX in patients with mCRC. The study endpoints were response rates, toxicity, progression free (PFS) and overall survival (OS). XELOX was administered as first line treatment to patients with mCRC. Patient selection criteria included histological confirmation of mCRC, ECOG performance status (PS) <or=2, and adequate bone marrow, renal and hepatic function. Patients received oxaliplatin 130 mg/m(2) i.v., day 1, and oral capecitabine 1000 mg/m(2) twice daily, days 1-14, every 3 weeks. 34 patients were treated with XELOX; males/ females 23/11, median age 53.5 years (range 42-65), ECOG PS 0/1 52%/48%. Metastatic sites were the liver (23/34; 67%), lung (7/34; 20%), and bone (4/34; 11%). No patient achieved complete response (CR), 14 patients showed partial response (PR), 8 stable disease (SD) and 11 progressed (PD). Median PFS was 5.5 months, median OS 12.9 months and 1-year survival 52%. The combination of oral capecitabine with i.v. oxaliplatin appears to be effective and well tolerated in patients with mCRC.
Document emailed within 1 workday
